JNK Isoforms Differentially Regulate Neurite Growth and Regeneration in Dopaminergic Neurons In Vitro by Tönges, Lars et al.
JNK Isoforms Differentially Regulate Neurite Growth
and Regeneration in Dopaminergic Neurons In Vitro
Lars Tönges & Veronique Planchamp &
Jan-Christoph Koch & Thomas Herdegen &
Mathias Bähr & Paul Lingor
Received: 19 January 2011 /Accepted: 24 March 2011 /Published online: 6 April 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Parkinson’s disease is characterized by selective
and progressive loss of midbrain DAergic neurons (MDN)
in the substantia nigra and degeneration of its nigrostriatal
projections. Whereas the cellular pathophysiology has been
closely linked to an activation of c-Jun N-terminal kinases
(JNKs) and c-Jun, the involvement of JNKs in regenerative
processes of the nigrostriatal pathway is controversially
discussed. In our study, we utilized a mechanical scratch
lesion paradigm of midbrain DAergic neurons in vitro and
studied regenerative neuritic outgrowth. After a siRNA-
mediated knockdown of each of the three JNK isoforms, we
found that JNKs differentially regulate neurite regeneration.
Knockdown of JNK3 resulted in the most prominent
neurite outgrowth impairment. This effect was attenuated
again by plasmid overexpression of JNK3. We also
evaluated cell survival of the affected neurons at the scratch
border. JNK3 was found to be also relevant for survival of
MDN which were lesioned by the scratch. Our data suggest
that JNK isoforms are involved in differential regulation of
cell death and regeneration in MDN depending on their
neurite integrity. JNK3 appears to be required for regener-
ation and survival in the case of an environment permissive
for regeneration. Future therapeutic approaches for the
DAergic system may thus require isoform specific targeting
of these kinases.
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Introduction
Parkinson’s disease (PD) is the second most common
aging-related neurodegenerative disorder and is character-
ized by progressive loss of dopaminergic (DAergic)
neurons in the substantia nigra pars compacta (SNpc) of
the midbrain (Olanow and Tatton 1999). Several gene
mutations have been linked to familial PD (Farrer 2006) but
the etiology of sporadic PD, which accounts for 90% to
95% of all PD cases, is largely undefined. Current
hypotheses attribute an increased risk for sporadic PD to
misfolding and aggregation of proteins, mitochondrial
dysfunction and oxidative stress. At the time of PD
diagnosis, about 80% of DAergic neuron terminals in the
striatum and 60% of DAergic neurons in the SNpc are
already lost in PD brains (Dauer and Przedborski 2003).
Today’s medical therapies can only focus on symptomatic
relief, and there is a great need to identify new therapeutic
targets for improved clinical performance. As studies
aiming to protect DAergic neurons in the SNpc have
largely failed (Olanow et al. 2008; Lohle and Reichmann
2010) there is increasing interest in DAergic axonal targets
which most likely play an earlier role in disease pathology
(Braak et al. 2003; Duda 2003; Conforti et al. 2007;
Lars Tönges and Veronique Planchamp contributed equally to this
work.
L. Tönges: V. Planchamp:J.-C. Koch:M. Bähr: P. Lingor (*)
Department of Neurology, University Medicine Göttingen,
R.-Koch-Str. 40,
37075 Göttingen, Germany
e-mail: plingor@gwdg.de
M. Bähr:P. Lingor
DFG Research Center for the Molecular Physiology of the Brain
(CMPB),
Göttingen, Germany
T. Herdegen
Institute of Pharmacology,
Universitätsklinikum Schleswig Holstein,
Campus Kiel,
Kiel, Germany
J Mol Neurosci (2011) 45:284–293
DOI 10.1007/s12031-011-9519-1Schulz-Schaeffer 2010) and may be the substrate of
regenerative approaches. For example, functional enhance-
ment and protection of DAergic terminals could signifi-
cantly improve clinical symptoms in animal models of
Parkinson’s disease (Chung et al. 2009).
The c-Jun N-terminal kinases (JNKs) are commonly
known as stress-activated protein kinases because their
activities typically increase in response to different cellular
environmental stresses like osmotic stress, redox stress, or
irradiation (Davis 2000; Weston and Davis 2002). Once
activated by a stress response or by inflammatory cytokines
they can also mediate cellular apoptosis (Kyriakis and
Avruch 1996; Ip and Davis 1998) - a function that is
particularly prominent in neurons and neuron-like cells (Xia
et al. 1995; Watson et al. 1998).
Increasing in vitro and in vivo evidence suggests a role
for JNK in the pathogenesis of DAergic neuron death in
several Parkinson’s disease models (Peng and Andersen
2003). As one example, the JNK pathway including its
upstream kinase MKK4 is activated in the nigrostriatal
system after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) application in mice (Saporito et al. 2000; Willesen
et al. 2002). Consequently, CEP-1347, a pharmacological
inhibitor of upstream kinases of JNK, was able to protect
from MPTP-induced JNK activation and nigrostriatal
DAergic neuron loss (Saporito et al. 1999). These data are
confirmed by later studies that in addition looked more
closely at destruction of axonal TH-positive DAergic
terminals in the striatum. Together with a protracted
expression and phosphorylation of c-Jun in the SNpc after
median forebrain bundle lesion Crocker et al. found a
pronounced loss of TH-positive terminals in the striatum.
Dominant-negative c-Jun did not only inhibit axotomy-
induced dopamine neuron death and attenuate phosphory-
lation of c-Jun in nigral neurons but also delayed the
degeneration of TH-positive DAergic terminals in the
striatum (Crocker et al. 2001). Systemic application of the
mixed lineage kinase inhibitor CEP11004 in the 6-
hydroxydopamine model of Parkinson’s disease inhibited
the loss of DA neurons in the SNpc and preserve TH-
positive striatal termini, too (Ganguly et al. 2004).
Whereas the aforementioned studies manipulated the entire
JNK pathway (mainly due to the lack of specific pharmaco-
logical inhibitors) there is evidence that the three mammalian
JNK proteins (Gupta et al. 1996) play different roles in the
context of cell survival and axon regeneration. Neuronal cell
stress was found to specifically activate only JNK2 and 3
(Coffey et al. 2002). The function of these two genes seems
to be closely related: in mice with single or double jnk2 and
jnk3 null mutations only the double null mutation could
protect from apoptosis in the intrastriatal 6-hydroxydopamine
neurotoxin model (Ries et al. 2008). These results are in
opposite to the lack of protection in the axonal compart-
ment, where rather intense axonal degeneration in the jnk2
and jnk3 null mutations was observed. Similarly, the
upstream blockade of the JNK pathway in the same animal
model using an adeno-associated virus vector delivery of
dominant-negative forms of dual leucine zipper kinase
strongly inhibited apoptosis and enhanced long-term
survival of DAergic neurons but did not protect their
axons (Chen et al. 2008).
In order to further clarify the role of the three JNK
proteins for axonal regeneration in DAergic neurons we
performed a study of differential siRNA-mediated knock-
down of JNK isoforms and evaluated neurite regenera-
tion and DAergic survival in the scratch paradigm of
mechanically transected primary neurons in culture
(Knoferle et al. 2010). We identify JNK3 as the most
important isoform regulating neurite outgrowth and
survival after lesion.
Materials and Methods
siRNAs and Plasmids
siRNA targeting rat JNK1, JNK2, JNK3 and EGFP (GFP-22
siRNA) were purchased from Qiagen (Hilden, Germany).
siRNA sequences are provided in Table 1.
Primary Midbrain Neuron Culture
Primary midbrain DAergic cultures were prepared accord-
ing to previously published protocols (Knoferle et al. 2010).
Briefly, the mesencephalon floor of embryonic day 14
Wistar rats was dissected and the meninges were removed.
The dissected tissue pieces were collected in ice-cold CMF
and centrifuged at 1,000 rpm for 4 min. Trypsin (750 μl,
Table 1 Sequences for JNK1, JNK2, JNK3, and EGFP siRNA
siRNA sequence Accession number Target sequence (bp)
JNK1 siRNA 5′ AGGCGAGAGATTTGTTATCTA 3′ XM_341399 1,003–1,023
JNK2 siRNA 5′ CTGGTGAAAGGTTGTGTGATA 3′ NM_017322 668–688
JNK3 siRNA 5′ TCCGTATGTGGTGACGAGATA 3′ NM_012806 912–932
EGFP siRNA 5′ CGGCAAGCTGACCCTGAAGTTCAT 3′– –
J Mol Neurosci (2011) 45:284–293 2850.25%, Sigma) was added to the tissue pellet and after
15 min of incubation at 37°C was inactivated with 750 μl
cold FCS. Tissue fragments were gently triturated, the cell
suspension was centrifuged at 1,000 rpm for 4 min and
resuspended in culture medium.
For RNA interference studies, 4×10
6 cells were trans-
fected with 0.3 μg siRNA and/or 0.5 μg plasmidic DNA
using Amaxa Nucleofector (Amaxa, Cologne, Germany).
Cells were then plated at a density of 500,000/well on 24-
well plates (Sarstedt, Nümbrecht, Germany) containing
coverslips coated with poly-D-lysine and laminin.
For JNK inhibition studies,cells wereplated ata density of
500,000/well on 24-well plates (Sarstedt) directly after
dissection. From day 3, cells were incubated with 5 μMo f
thesmall moleculeATP-competitive JNK inhibitorSP600125
(anthra(1,9-cd)pyrazol-6(2 H)-one; CalbioChem, Darmstadt,
Germany) or DMSO (AppliChem, Darmstadt, Germany) for
3 days before lysis/fixation (Bennett et al. 2001).
Cell cultures were maintained at 37°C in a 5% CO2
humified atmosphere in DMEM-F12 (Invitrogen) supple-
mented with 2.5 mg/ml BSA (35%), 0.9% D-(+)-glucose
solution (45%), 2 mM L-glutamine (PAA Laboratories,
Pasching, Austria), 5 μg/ml insulin, 1:100 N1 medium
supplement and 1:100 PSN antibiotic mixture (Invitrogen,
Scotland, UK) for 4, 7, or 9 days. Medium was changed 24 h
after cell dissection and subsequently every second day.
Scratch Assay and Phase Contrast Imaging
Three days following cell plating, cells were submitted to
mechanical transection using a self-made 2 mm broad silicon
rubber scratch device. Each coverslip was microscopically
examined to ensure completeness of the scratch. Three days
after mechanical transection (on day 6), cells were incubated
in a climate chamber for live cell imaging (37°C, 5%CO2)o n
a fluorescence inverted microscope (Axiovert, Zeiss, Ober-
kochen, Germany) equipped with a CCD camera and
AxioVision software (Zeiss, Göttingen, Germany). Contrast
phase photographs of three random visual fields per culture
well were taken with a 20× objective.
Immunocytochemistry
For DAergic cell visualization, cells were fixed after live
imaging on day 6 in PFA 4% 10 min at room temperature
(RT, 22°C), permeabilized with 100% ice-cold acetone
(AppliChem) 10 min at −20°C, washed twice with PBS and
blocked with 10% normalized goat serum 10 min at RT.
Probes were incubated with the primary antibodies (rat anti-
tyrosine hydroxylase 1:250 (Advanced Immunochemicals,
Long Beach, CA, USA) overnight at 4°C. Following 2 PBS
washes, appropriate Cy3- or Cy2-labeled secondary anti-
bodies (1:250, Dianova, Hamburg, Germany) were applied
for 45 min at 37°C. Cells were then nuclear counter-stained
with DAPI (4,6-diamidino-2-phenylindole) (Sigma, Tauf-
kirchen, Germany) and mounted in Mowiol (Hoechst,
Frankfurt, Germany). Fluorescence was observed and
recorded on a Zeiss Axioplan 2 fluorescence microscope
equipped with a CCD camera and AxioVision software
(Zeiss). For evaluation of DAergic regeneration and
survival at the scratch site, pictures of the entire scratch
site were taken with a 20× objective. For evaluation of
DAergic survival within the culture, pictures of two random
visual fields per culture well were taken with a 20×
objective.
Quantification of Regenerating Fibers
Neurite length was evaluated semi-automatically using the
axon tracing module of “Image J” (Free Java software
provided by the National Institutes of Health, Bethesda,
Maryland, USA). For evaluation of whole culture regener-
ation, the length of the 20 longest axons extending from the
scratch site of each photomicrograph was quantified.
Neurite length was defined as the neurite extension from
neurite tip to scratch site. For evaluation of DAergic
regeneration, length of all TH-labeled axons extending
from the scratch site of each photomicrograph was
quantified. The DAPI-labeled edge was used to identify
the scratch site. Results are expressed in % of EGFP-
transfected cells. Experiments were performed at least in
triplicate.
Quantification of DAergic Neuron Survival
For survival of DAergic neurons at the scratch site, the
number of TH-labeled cells located in the area comprising
the first 50 μm next to the scratch site was quantified.
Statistics
All in vitro experiments were reproduced at least in triplicate.
Differences between groups were considered statistically
significant according to a one-way ANOVA followed by a
parametric multiple comparison test (Dunnett’s test). Signifi-
cances were indicated with *p<0.05; **p<0.01; ***p<0.001,
unless otherwise stated.
Results
Pharmacological Inhibition of All JNK Isoforms (1, 2, and 3)
Impairs Neurite Regeneration of Primary DAergic Neurons
In order to evaluate the effect of a combined inhibition
of all three JNK isoforms we took advantage of the
286 J Mol Neurosci (2011) 45:284–293availability of the pharmacological small molecule ATP-
competitive pan-JNK inhibitor SP600125. Primary DAer-
gic neurons were cultured under standard conditions.
After 3 days neurites were mechanically transected and
SP600125 was applied at the same time. The evaluation
of neurite outgrowth of DAergic neurons from the
scratch border after another 3 days showed a significant-
ly decreased relative outgrowth of JNK inhibitor treated
total neurons (56.2±8.8%) in comparison to non-inhibitor
treated cells that were set to 100% (100±13.0%) (Fig. 1).
The same holds true for a specific analysis of only
DAergic neurons that show a decreased outgrowth after
JNK inhibitor treatment (64.4±32.8%) in comparison to
untreated DAergic neurons (100±15.9%). There was no
significant difference between regeneration of DAergic
and non-DAergic neurons.
siRNA-Mediated Downregulation of JNK3 Most
Significantly Impairs Regenerative Neurite Outgrowth
in Primary MDN
Midbrain DAergic neurons (MDN) cultures were separately
transfected with siRNAs directed against JNK1, 2, and 3.
After 3 days in vitro, the neurons were scratch lesioned and
their regenerative neurite outgrowth was evaluated after
another 3 days (Fig. 2). In comparison to the siEGFP
Fig. 1 SP600125 significantly
inhibits regenerative neurite out-
growth. a Representative micro-
graphs of MDN cultures at
3 days after scratch lesion (upper
panel, phase contrast; lower
panel,T H - C y 2( green)a n d
DAPI (blue)). Cultures were
treated with the pan-JNK-
inhibitor SP600125 (5 μM) or
DMSO control. Arrow,s i t eo f
mechanical transection (scratch
lesion). Scale bar,1 5 0μm. b
Treatment with the pan-JNK-
inhibitor SP600125 (5 μM)
significantly impairs neurite
regeneration of all primary cul-
tured neurons including TH-
positive DAergic subpopulation
after mechanical transection.
Data are from three independent
experiments each. Bars represent
means ± SEM; ***p<0.001
J Mol Neurosci (2011) 45:284–293 287control (100±11.4%), siJNK1 only slightly decreased
neurite outgrowth in the total population (85.6±10.2%).
This effect was more pronounced with siJNK2, which
reduced neurite outgrowth in the total population to 81.5±
10.7% and in DAergic neurons to 90.3±13.1%. Most
significantly, knockdown of JNK3 reduced neurite out-
growth to 72.0±9.7% in the total population and to 86.2±
14.4% in the DAergic neuron subpopulation.
siJNK3-Related Impaired Regenerative Response
Can Be Efficiently Rescued by Overexpression of JNK3
As the neurite regenerative outgrowth was most depen-
dent on the JNK3 isoform (Fig. 2), we overexpressed the
JNK3 protein in culture to evaluate the specificity of our
approach (Fig. 3). SiJNK3 transfection of MDN cultures
resulted in a significantly impaired neurite outgrowth after
s c r a t c hl e s i o nc o m p a r e dw i t hs i E G F Pt r a n s f e c t i o ni nt h e
total population (66.4±11.2% to 100.0±10.5%) and in the
DAergic subpopulation (70.5±11.9% to 100.0±16.9%) three
days after lesioning. Expression of pEGFP (total population,
93.3±12.1%; DAergic population, 122.8±22.5%) or pJNK3
alone (total population, 101.8±13.7%; DAergic population,
110.4±22.5%) did not significantly alter neurite outgrowth.
However, the combined transfection of siJNK3 with pJNK3
significantly rescued the siJNK3 mediated impairment of
neurite regeneration (total population, 94.5±13.8%; DAergic
population, 99.9±16.9%). This effect could not be rescued by
combined transfection of siJNK3 and pEGFP (total popula-
tion, 74.7±12.5%; DAergic population, 87.8±15.7%).
Fig. 2 Downregulation of JNK isoforms negatively influences
regenerative neurite outgrowth. a Representative micrographs of
MDN cultures at 3 days after scratch lesion (upper panel, phase
contrast; lower panel, TH-Cy2 (green) and DAPI (blue)). Cultures
were transfected with 0.3 μg of siRNA directed against EGFP, JNK1,
JNK2, or JNK3, respectively. Arrow, site of mechanical transection
(scratch lesion). Scale bar, 200 μm. b Quantitative analysis of neurite
length at 3 days after mechanical transection in MDN cultures treated
with different siRNAs for all neurons and for the DAergic subpop-
ulation only. Application of JNK3 siRNA (siJNK3, 0.3 μg) resulted in
the most significant decrease in neurite regeneration compared with
cells transfected with EGFP siRNA (siEGFP) as a control. Bars
represent means ± SEM. For all treatments, n=8.*p<0.05; **p<0.01;
***p<0.001
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Neurons Impairs Survival
Apart from their role in neurite regeneneration JNK
proteins play an important function in cell survival.
Therefore, we evaluated the number of surviving TH-
positive neurons at the scratch border after 6 days in culture
and siRNA transfection at DIV0 (Fig. 4). siJNK3 trans-
fected neurons demonstrated a significantly reduced sur-
vival (60.3±11.9%) compared with the siEGFP (100.0±
15.5%) as well as to the siJNK1 (101.0±15.4%) and
siJNK2 (89.8±10.8%) transfected neurons.
Fig. 3 JNK3 overexpression efficiently rescues the impaired regen-
erative response following JNK3 siRNA silencing. a Representative
micrographs of MDN cultures at 3 days after scratch lesion (left panel,
phase contrast; right panel, TH-Cy3 (red) and DAPI (blue)). Cultures
were transfected on DIV0 with siRNA against EGFP or JNK3, the
plasmids pEGFP or pJNK3, or a combination of JNK3 siRNA and
pEGFP or JNK3 siRNA and pJNK3. Arrow, site of scratch lesion.
Scale bar, 200 μm. b Quantitative analysis of neurite length at 3 days
after scrach lesion in MDN cultures treated with siRNA or plasmid
DNA as indicated. Neurite length is given for all neurons and for the
DAergic subpopulation only. Overexpression of JNK3 rescues the
siJNK3-mediated regeneration impairment, while transfection with
pEGFP does not have a significant effect on neurite regeneration. Data
are from three independent experiments each. Bars represent means ±
SEM. For all treatments, n=8. *p<0.05; **p<0.01; ***p<0.001
J Mol Neurosci (2011) 45:284–293 289Discussion
In search for putative targets for neurorestorative strategies
in Parkinson’s disease (PD), we studied the role of JNK
protein isoforms as they have been shown to participate in
the pathophysiology of DAergic degeneration (Peng and
Andersen 2003). We report here that the three JNK
isoforms play distinct roles for neurite regeneration of
DAergic neurons and that JNK3 seems to be the most
relevant isoform in the regeneration paradigm after me-
chanical neurite lesion.
Pharmacological Inhibition of JNK Negatively Affects
Neurite Regeneration
In the lesioned CNS, c-Jun phosphorylation occurs in
axotomized neurons and correlates with enhanced long-
term JNK activity (Herdegen et al. 1998). JNKs are able to
trigger both expression and activation of c-Jun in lesioned
neurons (Lindwall and Kanje 2005). However, several in
vitro studies have shown that JNKs are also involved in
neurite formation and stabilization (Leppa et al. 1998; Xiao
and Liu 2003).
In our study, pan-JNK inhibition with SP600125 led to a
severe impairment of neurite regeneration after scratch
lesion in all neurons including the DAergic subpopulation
(Fig. 1), which has been previously also reported for
unlesioned MN9D cells and primary DAergic neurons
(Eom et al. 2005). Thus, neurite growth in DAergic neurons
depends on JNK activity in both primary and regenerative
growth. Using RNAi technology we further investigated the
question, which JNK isoform specifically regulates survival
and regeneration in primary DAergic neurons.
Differential Role of JNK1, 2, and 3 for Neurite
Regeneration in Midbrain Neurons
In a previous study, we could demonstrate the importance
of distinct protein kinase families for growth cone collapse,
neurite retraction and neurite outgrowth (Loh et al. 2008).
We now show that the downregulation of all three JNK
isoforms regulates the regenerative response in the total
population, but only downregulation of JNK2 and even
more JNK3 had significant effects on the DAergic
subpopulation. Plasmid-mediated overexpression of JNK3
reversed the effect of single-time siRNA application and
thus confirmed the importance of JNK3 in regenerative
signaling. Interestingly, overexpression of JNK3 alone did
not result in an increased regenerative growth, suggesting
that JNK3 signaling is already saturated in this context.
JNK1 and JNK2 were previously shown to be involved
in neurite outgrowth in PC12 cells (Waetzig and Herdegen
2003b). Whereas JNK1 and JNK2 are expressed in a large
variety of tissues, the JNK3 isoform is restricted to brain,
heart, and testis (Gupta et al. 1996). Although JNK3 was
mainly attributed a pro-apoptotic function (Yang et al.
1997), it was also able to enhance NGF-induced sprouting
in PC12 cells that normally do not express JNK3 (Waetzig
and Herdegen 2003a). A putative explanation for JNK3-
associated neurite growth may be the fact that JNK3
together with JNK2 could be translocated to the nucleus
and thereby influence transcription of regeneration-
associated genes like c-Jun, ATF-3 (Lindwall et al. 2004),
as well as CD44, galanin and a7b1 integrin (Raivich et al.
2004; Raivich and Makwana 2007). Depending on cell type
and cellular context JNKs can bind and activate different
binding partners in so-called signalosomes and thus, in
principle, can trigger both degeneration and neurite out-
growth (Waetzig and Herdegen 2005; Waetzig et al. 2006).
For example, in an analysis using knockout mice for jnk1,
jnk2,o rjnk3, all animals presented a failure in neurito-
genesis of hippocampal neurons, most prominently in the
jnk3 knockout. However, this effect was not observed in
cortical neurons (Eminel et al. 2008). Even more
conflicting was the finding in cerebellar neurons, where
JNKs relatively inhibited neuritogenesis (Coffey et al.
2000). Very recently, a study analyzing axonal regeneration
in adult mouse dorsal root ganglion neurons demonstrated
that neuritogenesis is delayed by lack of JNK2 and JNK3
but not by JNK1. JNK1 and JNK2 were rather necessary
Fig. 4 JNK3 is important for
survival of mechanically
lesioned DAergic neurons.
Transfection of 0.3 μg of JNK3
siRNA significantly decreases
the number of surviving DAer-
gic neurons at the scratch border
compared with EGFP-, JNK1-
and JNK2-siRNA-transfected
neurons. For all treatments, n=
8. Experiments were repeated at
least three times with cells from
different cultures. Bars represent
means ± SEM. ***p<0.001
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phosphorylation state of microtubule-associated protein
MAP1b (Barnat et al. 2010). Our data support the notion
that JNK3 is most prominently involved in regulation of the
initial regenerative response in primary DAergic midbrain
neurons.
JNK3 Is Relevant for Survival of Mechanically Lesioned
DAergic Neurons
Our analysis demonstrated that JNK3-knockdown nega-
tively affects survival of lesioned DAergic neurons at the
scratch border (Fig. 4). Importantly, no general cell stressor
was applied in this paradigm which may be the reason for
the lack of detrimental signaling of JNK3. On the contrary,
the regenerating and previously lesioned neurons seemed to
partially depend on JNK3 since a downregulation resulted
in less survival.
JNK3 appears to function as a key player in apoptosis
(Waetzig and Herdegen 2003a). For example, jnk3 knockout
mice lack excitotoxicity-induced apoptosis in the hippocam-
pus (Yang et al. 1997). Targeted deletion of jnk3 did not only
reduce the stress-induced JNK activity, but also protected
mice from cerebral ischemia-hypoxia that was attributed in
part to a reduced expression of Bim and Fas (Kuan et al.
2003). Recently, the specific activation of the PI3K/Akt
pathway has been identified as an additional neuroprotective
mechanism by gene expression profiling in jnk3 knockout
mice (Junyent et al. 2011). Novel data further extend the
understanding of these processes by demonstrating that in
principle all JNKs can induce cell death, which is critically
dependent on nuclear localization and activation of cell death
pathways (Bjorkblom et al. 2008)
In the context of PD the JNK/c-Jun pathway and
especially the JNK3 isoform seem to play a leading role:
in a human autopsy study c-Jun was found activated in
DAergic neurons from PD patients—a result that was
equally observed in the MPTP mouse model of PD (Hunot
et al. 2004). In the same study, an examination of various
JNK-deficient mice showed that both JNK2 and JNK3, but
not JNK1, were required for MPTP-induced c-Jun activa-
tion and DAergic cell demise. Mice deficient for JNK3
showed also an enhanced and lasting survival of the MFB
axotomized DAergic neurons in the SNpc (Brecht et al.
2005). JNK3 was also shown to mediate paraquat- and
rotenone-induced DAergic neuron death, which could be
attenuated by pharmacologically blocking translocation and
activation of JNK3 (Choi et al. 2010). However, low JNK3
levels were not able to attenuate striatal dopamine terminal
loss (Pan et al. 2009). In vivo studies in JNK3 or JNK2/3
knockout mice were not able to demonstrate axonal
regenerative effects in a model of glaucoma (Quigley et
al. 2011) or in an experimental model of PD (Cheng et al.
2010), which may be due to the more complex in vivo
situation involving compensatory mechanisms in these
genetically modified mice. Induced models to interfere
with JNK3 signaling could possibly shed more light on the
situation in vivo.
To this end, specific small molecule inhibitors of the
JNK isoforms including JNK3 have been recently devel-
oped (Bowers et al. 2011; He et al. 2011; Probst et al. 2011;
Schattel et al. 2011) and could be complementary to gene
therapeutic approaches using siRNA/shRNA. Nevertheless,
even with improved cell permeability of such JNK3
inhibitors, the achievement of a balanced specific spatial
and temporal cellular inhibitory activity in vivo will still be
required (Antoniou et al. 2011).
Studies on autopsy cases from patients treated with
intraputaminal GDNF injections impressively demonstrate
that regeneration can take place in PD (Love et al. 2005).
Therefore, there is evidence to consider axonal regeneration
as a therapeutic target mechanism in addition to neuro-
protection in PD.
Taken together, we have shown that inhibition of JNK3
may result in a detrimental outcome regarding survival of
previously lesioned and subsequently regenerating DAergic
neurons. In our paradigm, JNK3 appears to be required for
both axonal regeneration and survival. Thus, our results
strongly support a pro-regenenerative role of JNK3 and
attribute a pro-survival role specifically for lesioned
dopaminergic neurons.
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